They found that sMICA hindered the activation of NKG2D signaling in NK cells, reduced the generation of cytokines such as IFN-γ, TNF-α, and IL-8 by NK cells, and decreased the expression of CD107a, a specific marker of NK cell activation, thereby impairing the anti-tumor immune response of the body [59]. This evidence concerns the gene KLRK1 and neoplasm.